APA (7th ed.) Citation

Burnett, A., El Rassi, F., Darbari, D., Paulose, J., Lainé, D., Purkayastha, D., & Kato, G. (2020). 147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). Journal of Sexual Medicine, 17, S43. https://doi.org/10.1016/j.jsxm.2019.11.092

Chicago Style (17th ed.) Citation

Burnett, A., F. El Rassi, D. Darbari, J. Paulose, D. Lainé, D. Purkayastha, and G. Kato. "147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN)." Journal of Sexual Medicine 17 (2020): S43. https://doi.org/10.1016/j.jsxm.2019.11.092.

MLA (9th ed.) Citation

Burnett, A., et al. "147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN)." Journal of Sexual Medicine, vol. 17, 2020, p. S43, https://doi.org/10.1016/j.jsxm.2019.11.092.